All In Biotech

Drug Trial Radar · NCT04417621

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma

Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 134 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

134

Actual

Start

Oct 30, 2020

Primary completion

Feb 2, 2027

Study completion Feb 2, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma

Conditions

  • Melanoma

Interventions

  • LXH254Drug

    LXH254 will be supplied as tablet for oral use.

  • LTT462Drug

    LTT462 will be supplied as hard gelatin capsule for oral use.

  • TrametinibDrug

    Trametinib will be supplied as film-coated tablet for oral use

  • RibociclibDrug

    Ribociclib will be supplied in tablets and hard gelatin capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response RateTime frame: 35 months

Locations

36 sites in 12 countries. Site status is shown where the registry gives one.

  • The Angeles Clinic and Research Institute

    Los Angeles, California

  • UCSF Medical Center

    San Francisco, California

  • Florida Cancer Specialists

    Fort Myers, Florida

  • H Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Mayo Clinic Mayo Rochester

    Rochester, Minnesota

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • NYU Laura and Isaac Perlmutter Cancer Center

    New York, New York

  • Memorial Sloan Kettering

    New York, New York

  • University of Pittsburgh Med Center

    Pittsburgh, Pennsylvania

  • Univ of TX MD Anderson Cancer Cntr

    Houston, Texas

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    North Sydney, New South Wales, Australia

  • Novartis Investigative Site

    Wooloongabba, Queensland, Australia

  • Novartis Investigative Site

    Subiaco, Western Australia, Australia

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Wilrijk, Belgium

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Pierre-Bénite, France

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Villejuif, France

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Heidelberg, Germany

  • Novartis Investigative Site

    Tübingen, Germany

  • Novartis Investigative Site

    Dresden, Saxony, Germany

  • Novartis Investigative Site

    Ramat Gan, Israel

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Maastricht, Limburg, Netherlands

  • Novartis Investigative Site

    Oslo, Norway

  • Novartis Investigative Site

    Lausanne, Switzerland

  • Novartis Investigative Site

    Zurich, Switzerland

  • Novartis Investigative Site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.